Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arixtra adds treatment indications

Executive Summary

Sanofi-Synthelabo's antithrombotic Arixtra (fondaparinux) clears FDA May 28 for treatment of deep vein thrombosis and pulmonary embolism. The product, previously approved for prophylactic use in patients undergoing hip fracture surgery and hip or knee replacement, is being divested to GlaxoSmithKline in conjunction with Sanofi's pending acquisition of Aventis (1"The Pink Sheet" April 19, 2004, p. 18)...
Advertisement

Related Content

GSK Will Buy Arixtra From Sanofi If Aventis Merger Goes Through
GSK Will Buy Arixtra From Sanofi If Aventis Merger Goes Through
Advertisement
UsernamePublicRestriction

Register

PS044100

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel